Gongwin Biopharm Holdings Co., Ltd. (TPEX:6617)

Market Cap	13.17B
Revenue (ttm)	32.04M
Net Income (ttm)	-82.55M
Shares Out	126.60M
EPS (ttm)	-0.68
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	82,601
Average Volume	101,613
Open	103.50
Previous Close	101.50
Day's Range	98.00 - 103.50
52-Week Range	94.50 - 200.00
Beta	0.64
RSI	47.32
Earnings Date	Mar 13, 2025

About Gongwin Biopharm Holdings

Gongwin Biopharm Holdings Co., Ltd., a clinical-stage biopharmaceutical company, develops anticancer drugs. It is developing PTS302, which has completed Phase III clinical trials for the treatment of lung cancer; PTS100, which is in Phase II clinical trials for the treatment of liver cancer; PTS-02 for the treatment of adenoid cystic carcinoma; and PTS500 for the treatment of malignant pleural effusion. The company was founded in 2014 and is based in Taipei, Taiwan.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Country: Cayman Islands
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6617

Financial Performance

In 2024, Gongwin Biopharm Holdings's revenue was 32.04 million, an increase of 69.39% compared to the previous year's 18.92 million. Losses were -82.55 million, -18.41% less than in 2023.